Regarding colon cancer treatment, researchers proved the feasibility of coupling Doxil® with anti-CD44 mAb [90] and anti-CD133 mAb [91] and accomplished higher therapeutic efficacy compared to other treatments (non-targeted Doxil® and free DOX) against CD44-positive C-26 cells (in vitro and in vivo) and CD133-positive HT-29 cells, respectively. This evidence concerns the gene PROM1 and colonic neoplasm.